S&P 500 Healthcare Sector SEC Filings — June 26, 2026

Net sales grew 3.4% YoY to $22.95B in 2025, with MedSurg & Neurotechnology up 3.8% YoY ($12.35B vs $11.89B) and Orthopaedics up 2.9% YoY ($10.61B vs $10.31B), indicating consistent execution across core segments

Knees segment grew 4.9% YoY to $3.20B in 2025 from $3.05B in 2024, outperforming the Orthopaedics segment average growth of 2.9%, signaling strong demand in joint replacement

Hips segment grew 3.7% YoY to $2.80B in 2025 from $2.70B in 2024, maintaining steady growth trajectory in a mature market

Spinal Implants declined within Orthopaedics, creating a mixed segment performance that warrants monitoring for competitive or pricing pressures

EVP & Chief Revenue Officer sold only 75 shares at $152.80 (~$11.5K) under a pre-arranged 10b5-1 plan, representing a trivial reduction in holdings (21,009 shares remain), with no bearish signal for management conviction

Net sales grew 12% from $20.50B in 2023 to $22.95B in 2025, a two-year CAGR of ~5.8%, demonstrating sustained organic growth in a competitive medtech landscape

MedSurg & Neurotechnology segment grew 12.7% from $10.95B in 2023 to $12.35B in 2025, outperforming Orthopaedics' 11.1% growth over the same period, suggesting stronger momentum in surgical and neurotech products

Spinal Implants within Orthopaedics declined in 2025, breaking the segment's overall growth trend and suggesting potential market share loss, pricing pressure, or product cycle headwinds

Orthopaedics segment growth slowed to 2.9% YoY in 2025 from 7.9% in 2024 (implied from $9.55B to $10.31B), indicating potential maturation or competitive pressures in core joint replacement markets

While the sale is tiny, any insider sale—even under a 10b5-1 plan—can be perceived negatively by retail investors if not contextualized, creating short-term sentiment risk

The filing does not provide gross margin, operating margin, or net income trends, leaving profitability trajectory unclear despite revenue growth; margin compression could offset top-line gains

The 8-K filing lacks forward-looking statements or guidance, creating uncertainty about management's outlook for 2026 and beyond, especially given mixed segment performance

MedSurg & Neurotechnology growth slowed to 3.8% YoY in 2025 from 8.6% in 2024 (implied from $10.95B to $11.89B), suggesting a potential normalization after a strong post-pandemic recovery

With $12.35B in 2025 sales and 12.7% growth over two years, Stryker's MedSurg & Neurotechnology segment is a cash cow; investors can capitalize on continued elective procedure volume recovery and new product cycles

Knees growing 4.9% YoY vs segment average 2.9% signals strong market share gains or technology adoption (e.g., robotic-assisted surgery); this sub-segment could be a catalyst for further Orthopaedics acceleration

At ~$22.95B in sales with consistent 3-5% organic growth, Stryker may be undervalued if the market is pricing in a slowdown; the mixed Orthopaedics result could create a buying opportunity for long-term investors

Hips growing 3.7% YoY provides predictable revenue in a demographic-driven market (aging population); this steady performer supports dividend and reinvestment capacity

The trivial insider sale at BD creates no real risk; contrarian investors may view the stock as oversold if the market overreacts, especially given BD's diversified medtech portfolio

If Spinal Implants decline is due to a product transition (e.g., new minimally invasive systems), a recovery in 2026 could provide upside; watch for upcoming earnings calls for details

Both Stryker and BD (implied from its scale) show that large-cap medtech continues to grow, with Stryker's 3.4% YoY growth in 2025 reflecting steady demand for surgical and orthopedic products despite macro headwinds

Stryker's data reveals that Knees and Hips are growing (4.9% and 3.7% YoY) while Spinal Implants decline, highlighting a sector-wide trend where large joint replacement outperforms spine surgery, possibly due to pricing pressure or shift to outpatient settings

Only one insider trade (BD's trivial sale) was reported across two filings, suggesting no broad-based management concern or conviction signal in the healthcare sector from this data set

Neither filing provides guidance, targets, or forecasts, indicating that investors must rely on upcoming earnings calls (potentially in Q2 2026) for directional cues, creating a near-term information vacuum

No dividend, buyback, or M&A data in these filings, suggesting that shareholder return policies are not a focus in this batch; investors should seek separate filings for capital allocation insights

Watch for Q2 2026 earnings call (likely July 2026) for forward guidance on Orthopaedics, especially Spinal Implants recovery and margin trends; any guidance raise would be bullish

Monitor for additional disclosures on Spinal Implants decline—whether due to competition, pricing, or product transition—as a key risk factor for 2026 performance

Watch for any larger insider sales or purchases at BD in coming weeks; the trivial sale is a non-event, but a pattern of selling by multiple executives would be a red flag

Track whether MedSurg & Neurotechnology growth re-accelerates in Q2 2026; a slowdown below 3% YoY would signal market saturation or competitive losses

Stryker has a history of bolt-on acquisitions; any deal announcements in 2026 could boost growth in Spinal or Neurotechnology segments

Monitor competitive dynamics in knees (e.g., Zimmer Biomet, Smith+Nephew); Stryker's 4.9% growth may indicate share gains that could be a long-term catalyst